AnaptysBio's asthma therapy improves eosinophil count and lung function in Phase IIa

AnaptysBio Inc. (NASDAQ:ANAB) reported interim data from a Phase IIa trial to treat severe eosinophilic asthma showing that etokimab (formerly ANB020) improved eosinophil count and lung function vs. placebo.

A single 300 mg dose of IV etokimab led to placebo-adjusted reductions from baseline in blood eosinophil count of 31% at day two and of 46% at day 64. Etokimab also led to placebo-adjusted improvements in forced expiratory volume in 1 second (FEV1) of 8% at day two and of 11% at day 64. Etokimab was generally well tolerated with no serious adverse events reported...